A NSW Government website


Gynae-Oncology Research

The Gynae-Oncology Department provide care for women with all types and stages of gynaecological cancers. The studies we undertake explore a variety of research directions. These include collecting information regarding registries, tissue collection for biobank and translational research, exploring different clinical, surgical and oncology treatments, effects of conventional and non-conventional pain management, investigating the effects of exercise during chemotherapy and end of life care. We aim to continuously expand our understanding of gynaecological cancers with the research we conduct.

Our Research Team

Associate Professor Rhonda Farrell Director of Gynae-Oncology
Associate Professor Selvan Pather Senior Staff Specialist Gynae-Oncology
Associate Professor Trevor Tedaja-Berges  Senior Staff Specialist Gynae-Oncology
Associate Professor Samir Saidi Senior Staff Specialist Gynae-Oncology
Dr Robyn Sayer Senior Staff Specialist Gynae-Oncology
Dr Michelle Harrison Senior Staff Specialist Medical Oncology
Dr Yeh-Lee Chen Senior Staff Specialist Medical Oncology
Dr Angela Line Fellow
Dr Gaithri Mylvaganam Fellow
Dr Jonathan Sandeford Fellow
Dr Alyssa Mahon Fellow
Dr Sadaf Kalam Clinical Trials Coordinator
Shannon Philp Nurse Practitioner
Belinda Zielony Clinical Nurse Consultant
Karthik Akula Data Manager 
Kyra Garland Masters Student

Selected Grants

Amount awarded Grant and project details
$3,700,000 Cancer Institute NSW and Cancer Council NSW, 2021-2024
INOVATe Individualised Ovarian Cancer Treatment through Integration of Genomic Pathology into Multidisciplinary Care.
RPA Investigator: Beale P
$3,520,935 MRFF, 2020-2023
Measuring adherence to best practice guidelines for the management of ovarian cancer in Australia to determine the extent to which variation in care influences clinical and patient-reported outcome.
Investigators: Zalcberg J, Rome R, Antony J, Schofield P, Brand A, Richardson G, Farrell R , Evans S, Hegarty S, , Earnest A. 
$686,674 MRFF Reproductive Cancers, 2020-2023
HyNOVA- A randomised study comparing hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer.
Investigators: Farrell R, Brand A, McNally O, Ford C, Coward J, Ananda S, Robledo K, Merciera-Bebber R, Koh C, Harrison M, Richards A, Rapajic Moran I, Warton K, Perrin L, Nascimento M, Stockler M, Ansari N, Chetty N, Beale P, Beach R, Pather S, Yip S, Gebski V, Lee YC. 
$40,000 Chris O'Brien Lifehouse Research Grant, 2022-2025
Diagnostic performance of diffusion-weighted MRI compared to laparoscopy in predicting feasibility of complete cytoreduction in advanced ovarian, fallopian tube and primary peritoneal cancer. 
Investigators: Farrell R, McGauran M, YuXuan Y, Lam K,  McNally O, Shadbolt C, Kouloyan-Ilic S. 
$33,520 Gynae-Oncology Research Advisory Group (GORAG) Research Grants, 2022-2024
Endo-3, phase III randomised trial comparing sentinel node biopsy with no node dissection in early-stage endometrial cancer.
Investigator: Farrell R.
$21,060 Gynae-Oncology Research Advisory Group (GORAG) Research Grants, 2022-2024
The role of virtual reality in reducing perioperative anxiety in Gynaecologic Oncology patients, a prospective randomized controlled study.
Investigator: Pather S.

Our Publications


Campbell R, Costa DSJ, Stockler MR, Lee YC, Ledermann JA, Berton D, Sehouli J, Roncolato FT, O'Connell R, Okamoto A, Bryce J, Oza AM, Avall-Lundqvist E, Berek JS, Lanceley A, Joly F, Hilpert F, Feeney A, Kaminsky MC, Diamante K, Friedlander ML, King MT, GCIG Symptom Benefit Group: Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. Gynecol Oncol 2022 Aug;166(2):254-262. DOI: 10.1016/j.ygyno.2022.05.024
Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed DW, Christie E, Fereday S, Andrews L, Lewis A, Limb S, Pandey A, Hendley J, Traficante N, Carvajal N, Spurdle AB, Thompson B, Parsons MT, Beshay V, Volcheck M, Semple T, Lupat R, Doig K, Yu J, Chen XQ, Marsh A, Love C, Bilic S, Beilin M, Nichols CB, Greer C, Lee YC, Gerty S, Gill L, Newton E, Howard J, Williams R, Norris C, Stephens AN, Tutty E, Smyth C, O'Connell S, Jobling T, Stewart CJR, Tan A, Fox SB, Pachter N, Li J, Ellul J, Mir Arnau G, Young MA, Gordon L, Forrest L, Harris M, Livingstone K, Hill J, Chenevix-Trench G, Cohen PA, Webb PM, Friedlander M, James P, Bowtell D, Alsop K, Australian Ovarian Cancer Study OCP, Lifestyle S, the TS: TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. J Clin Oncol: JCO2102108, 2022. DOI: 10.1200/JCO.21.02108
Dokter E, Anderson L, Cho SM, Cohen-Hallaleh V, Lam KM, Saidi SA, Kitzing YX. Radiology-pathology correlation of endometrial carcinoma assessment on magnetic resonance imaging. Insights Imaging. 2022 Apr 25;13(1):80. doi: 10.1186/s13244-022-01218-3. PMID: 35467253; PMCID: PMC9038982.
Farrell R, Burling M, Lee YC, Pather S, Robledo K, Mercieca-Bebber R, Stockler M; HyNOVA Protocol Steering Committee. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020). J Gynecol Oncol. 2022 Jan;33(1):e1. doi: 10.3802/jgo.2022.33.e1. Epub 2021 Oct 18. PMID: 34783204; PMCID: PMC8728663.
Farrell R, Liauw WS, Morris DL. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20 years' experience. BMC Surg. 2022 Sep 12;22(1):338. doi: 10.1186/s12893-022-01786-7. PMID: 36096791; PMCID: PMC9469563.
Feddersen J, Carter J, Pather S, Saidi SA. Identifying risk factors for post-operative bleeding in women undergoing loop electrosurgical excision procedure for cervical dysplasia. Aust N Z J Obstet Gynaecol. 2022 Oct;62(5):740-747. doi: 10.1111/ajo.13575. Epub 2022 Jul 29. PMID: 35904168; PMCID: PMC9796019.
Hill S, Anderson L, Pather S. Metastatic ovarian disease following surgical management of grade 1 endometrial endometrioid adenocarcinoma confined to the endometrium; a case report and review of the literature. Gynecol Oncol Rep. 2022 Aug 5;43:101061. doi: 10.1016/j.gore.2022.101061. PMID: 35967832; PMCID: PMC9372595.
Hodge, T., Naaman, Y. , Cade, T. , Neesham, D. , Jones, A. and McNally, O. (2022) Patterns of Recurrence in Low-Risk Endometrial Cancer. Open Journal of Obstetrics and Gynecology, 12, 1155-1165. doi: 10.4236/ojog.2022.1211100.
Hooshmand K, Goldstein D, Timmins HC, Li T, Harrison M, Friedlander ML, Lewis CR, Lees JG, Moalem-Taylor G, Guennewig B, Park SB, Kwok JB. Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study. J Transl Med. 2022 Dec 6;20(1):564. doi: 10.1186/s12967-022-03754-4. PMID: 36474270; PMCID: PMC9724416.
Ip E, Young AL, Scheinberg T, Harrison M, Beale P, Goodwin A. Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer. Asia Pac J Clin Oncol. 2022 Oct;18(5):e414-e419. doi: 10.1111/ajco.13741. Epub 2022 Jan 30. PMID: 35098668.
Kaakoush NO, Olzomer EM, Kosasih M, Martin AR, Fargah F, Lambie N, Susic D, Hoehn KL, Farrell R, Byrne FL. Differences in the Active Endometrial Microbiota across Body Weight and Cancer in Humans and Mice. Cancers (Basel). 2022 Apr 25;14(9):2141. doi: 10.3390/cancers14092141. PMID: 35565271; PMCID: PMC9100094.
Kalam SN, Dowland S, Lindsay L, Murphy CR. Porosomes in uterine epithelial cells: Ultrastructural identification and characterization during early pregnancy. J Morphol. 2022 Nov;283(11):1381-1389. doi: 10.1002/jmor.21504. Epub 2022 Oct 7. PMID: 36059156; PMCID: PMC9828572. 
Kang EY, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Da-Anoy A, Lambrechts D, Loverix L, Olbrecht S, Bisinotto C, Garcia-Donas J, Ruiz-Llorente S, Yagüe-Fernandez M, Edwards RP, Elishaev E, Olawaiye A, Taylor S, Ataseven B, du Bois A, Harter P, Lester J, Høgdall CK, Armasu SM, Huang Y, Vierkant RA, Wang C, Winham SJ, Heublein S, Kommoss FKF, Cramer DW, Sasamoto N, van-Wagensveld L, Lycke M, Mateoiu C, Joseph J, Pike MC, Odunsi K, Tseng CC, Pearce CL, Bilic S, Conrads TP, Hartmann A, Hein A, Jones ME, Leung Y, Beckmann MW, Ruebner M, Schoemaker MJ, Terry KL, El-Bahrawy MA, Coulson P, Etter JL, LaVigne-Mager K, Andress J, Grube M, Fischer A, Neudeck N, Robertson G, Farrell R, Barlow E, Quinn C, Hettiaratchi A, Casablanca Y, Erber R, Stewart CJR, Tan A, Yu Y, Boros J, Brand AH, Harnett PR, Kennedy CJ, Nevins N, Morgan T, Fasching PA, Vergote I, Swerdlow AJ, Candido Dos Reis FJ, Maxwell GL, Neuhausen SL, Barquin-Garcia A, Modugno F, Moysich KB, Crowe PJ, Hirasawa A, Heitz F, Karlan BY, Goode EL, Sinn P, Horlings HM, Høgdall E, Sundfeldt K, Kommoss S, Staebler A, Wu AH, Cohen PA, DeFazio A, Lee CH, Steed H, Le ND, Gayther SA, Lawrenson K, Pharoah PDP, Konecny G, Cook LS, Ramus SJ, Kelemen LE, Köbel M. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Arch. 2022 Apr;480(4):855-871. doi: 10.1007/s00428-021-03232-0. Epub 2021 Nov 15. PMID: 34782936; PMCID: PMC9035053.
Krasovitsky M, Lee YC, Sim HW, Chawla T, Moore H, Moses D, Baker L, Mandel C, Kielar A, Hartery A, O'Malley M, Friedlander M, Oza A, Wang L, Lheureux S, Wilson M. Inter- and Intra- Observer Variability o fRECIST Assessment in Ovarian Cancer. Int J Gynecol Cancer 2022;32:656-661. DOI: 10.1136/ijgc-2021-003319
Lee YC, King MT, O'Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML, GCIG Symptom Benefit Group: Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. Int J Gynecol Cancer 2022;32:761-768. DOI: 10.1136/ijgc-2021-003142
Mahfouz FM, Park SB, Li T, Timmins HC, Horvath LG, Harrison M, Grimison P, King T, Goldstein D, Mizrahi D. Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients. Clin Auton Res. 2022 Dec;32(6):497-506. doi: 10.1007/s10286-022-00895-w. Epub 2022 Sep 21. PMID: 36129622; PMCID: PMC9719444.
McCarthy RL, Farrell R, Lochhead A, Anderson L. A case of mesonephric-like adenocarcioma of the ovary. Pathology 2022;54:S1:S53 doi: org/10.1016/j.pathology.2021.12.172
Meagher NS, Gorringe KL, Wakefield M, Bolithon A, Pang CNI, Chiu DS, Anglesio MS, Mallitt KA, Doherty JA, Harris HR, Schildkraut JM, Berchuck A, Cushing-Haugen KL, Chezar K, Chou A, Tan A, Alsop J, Barlow E, Beckmann MW, Boros J, Bowtell DDL; AOCS Group; Brand AH, Brenton JD, Campbell I, Cheasley D, Cohen J, Cybulski C, Elishaev E, Erber R, Farrell R, Fischer A, Fu Z, Gilks B, Gill AJ; Australian Pancreatic Genome Initiative; Gourley C, Grube M, Harnett PR, Hartmann A, Hettiaratchi A, Høgdall CK, Huzarski T, Jakubowska A, Jimenez-Linan M, Kennedy CJ, Kim BG, Kim JW, Kim JH, Klett K, Koziak JM, Lai T, Laslavic A, Lester J, Leung Y, Li N, Liauw W, Lim BWX, Linder A, Lubiński J, Mahale S, Mateoiu C, McInerny S, Menkiszak J, Minoo P, Mittelstadt S, Morris D, Orsulic S, Park SY, Pearce CL, Pearson JV, Pike MC, Quinn CM, Mohan GR, Rao J, Riggan MJ, Ruebner M, Salfinger S, Scott CL, Shah M, Steed H, Stewart CJR, Subramanian D, Sung S, Tang K, Timpson P, Ward RL, Wiedenhoefer R, Thorne H; kConFab Investigators; Cohen PA, Crowe P, Fasching PA, Gronwald J, Hawkins NJ, Høgdall E, Huntsman DG, James PA, Karlan BY, Kelemen LE, Kommoss S, Konecny GE, Modugno F, Park SK, Staebler A, Sundfeldt K, Wu AH, Talhouk A, Pharoah PDP, Anderson L, DeFazio A, Köbel M, Friedlander ML, Ramus SJ. Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. Clin Cancer Res. 2022 Dec 15;28(24):5383-5395. doi: 10.1158/1078-0432.CCR-22-1206. PMID: 36222710; PMCID: PMC9751776.
Obermair A, McNally O, Farrell R, Ribeiro R, Ng JS. Are endometrial cancer clinical practice management guidelines sufficiently consumer centric? Int J Gynecol Cancer. 2022 Jul 4;32(7):961-962. doi: 10.1136/ijgc-2022-003580. PMID: 35478093; PMCID: PMC9279834.
Ooi S, Eskaroos MA, Pather S, Carter J, Saidi S. Patient expectations and experiences with loop electrosurgical excision procedure in inpatient and outpatient settings. Aust N Z J Obstet Gynaecol. 2022 Oct;62(5):720-724. doi: 10.1111/ajo.13556. Epub 2022 Jun 28. PMID: 35762277.
Robson D, de Vries B, Pather S, Marren A. Fertility preservation in gynaecology oncology patients: Experience from an Australian tertiary oncology centre. Aust N Z J Obstet Gynaecol. 2022 Aug;62(4):542-547. doi: 10.1111/ajo.13498. Epub 2022 Feb 15. PMID: 35166382.
Sivakumaran T, Krasovitsky M, Freimund A, Lee YC, Webber K, So J, Norris C, Friedlander M, Mileshkin L, Au-Yeung G. Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients. Int J Gynecol Cancer, 2022. DOI: 10.1136/ijgc-2021-003009
Sykes PH, Simcock BJ, Innes CR, Harker D, Williman JA, Whitehead M, van der Griend RA, Lawton BA, Hibma M, Fitzgerald P, Dudley NM, Petrich S, Eva L, Bergzoll C, Kathuria J, McPherson G, Tristram A, Faherty J, Hardie D, Robertson A, Robertson V, Pather S, Wrede CD, Gastrell F, Fentiman G, John M, White E, Parker C, Sadler L. Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years. Am J Obstet Gynecol. 2022 Feb;226(2):222.e1-222.e13. doi: 10.1016/j.ajog.2021.09.009. Epub 2021 Sep 14. PMID: 34534506.
Takenaka K, Curry-Hyde A, Olzomer EM, Farrell R, Byrne FL, Janitz M. Investigation of Transcriptome Patterns in Endometrial Cancers from Obese and Lean Women. Int J Mol Sci. 2022 Sep 29;23(19):11471. doi: 10.3390/ijms231911471. PMID: 36232772; PMCID: PMC9569830.
Teoh J, Pather S, Narayan R. Use of an Arabin pessary to prevent preterm birth in pregnancy complicated by a short cervix after cervical conization for cervical adenocarcinoma with residual disease: A case report and literature review. Case Rep Womens Health. 2022 Aug 5;36:e00437. doi: 10.1016/j.crwh.2022.e00437. PMID: 35991521; PMCID: PMC9385544.
Timmins HC, Li T, Goldstein D, Trinh T, Mizrahi D, Harrison M, Horvath LG, Friedlander M, Kiernan MC, Park SB. The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. J Cancer Surviv. 2022 Apr;16(2):223-232. doi: 10.1007/s11764-021-01012-y. Epub 2021 Feb 27. PMID: 33641031.
Woopen H, Sehouli J, Davis A, Lee YC, Cohen PA, Ferrero A, Gleeson N, Jhingran A, Kajimoto Y, Mayadev J, Barretina-Ginesta MP, Sundar S, Suzuki N, van Dorst E, Joly F. GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee. Cancer Treatment Reviews 2022;107: 102396. DOI: 10.1016/j.ctrv.2022.102396